Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study

Abstract

Background The complement system is involved in pathogenesis of cardiovascular disease, and might play a role in accelerated atherogenesis in spondylarthropathies (SpA). Hence, we examined complement activation in SpA, and its relationship to antirheumatic treatment, inflammatory and cardiovascular markers. Methods From PSARA, a prospective observational study, we examined 51 SpA patients (31 psoriatic arthritis (PsA), and 20 ankylosing spondylitis (AS)), starting tumor necrosis factor (TNF) inhibitor alone (n = 25), combined with methotrexate (MTX) (n = 10), or MTX monotherapy (n = 16). Complement activation was determined by the soluble terminal complement complex (sC5b-9), inflammation by erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and endothelial function by finger plethysmography (Endopat) at baseline, after 6 weeks and 6 months of treatment. Results SpA patients had sC5b-9 levels at (PsA) or above (AS) the upper limit of the estimated reference range. Median sC5b-9 levels decreased significantly from baseline to 6 weeks, with no significant difference between the AS and PsA group. Notably, a significant reduction in sC5b-9 was observed after administration of TNF inhibitor ± MTX, whereas no significant changes were observed in patients treated with MTX alone. Between 6 weeks and 6 months, sC5b-9 remained stable across all subgroups. Reduction in sC5b-9 was independently related to decreased ESR and CRP, and to increased high density cholesterol and total cholesterol. Reduction in sC5b-9 from baseline to 6 weeks was associated with improved EF in age and gender adjusted analyses. Conclusion TNF-inhibition, but not MTX monotherapy, led to rapid and sustained reduction of complement activation in SpA. Thus, the observed decrease in cardiovascular morbidity in patients treated with TNF-inhibitors might be partly due to its beneficial effect on complement. Trial registration Clinical Trials ( NCT00902005 ), retrospectively registered on the 14 th of May 2009.

Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis

“…The presence of increased complement activation in autoimmune arthritis, such as RA and spondyloarthropathies, has been reported before [14][15][16]40], and is confirmed by the results of…”

Soluble Membrane Attack Complex: Biochemistry and Immunobiology

“…This could include patients being treated for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome ( 106 , 221 , 222 ), age-related macular degeneration ( 107 ), glomerulonephritis ( 223 ), hematopoietic stem cell transplantation (transplant associated thrombotic microangiopathy) ( 224 ), thrombotic thrombocytopenia purpura ( 108 , 225 ), and acute post-infectious glomerulonephritis ( 226 ). sMAC monitoring may also have diagnostic value in anti-TNF-α treatment of spondylarthropathies ( 227 ), indicating the diagnostic value of sMAC exists beyond complement-specific therapeutics. By extension, sMAC may have diagnostic value in monitoring treatment in rheumatoid, psoriatic arthritis, and other autoimmune diseases given the findings in spondylarthropathies.…”

Synovial Complement Factors in Patients with Periprosthetic Joint Infection after Undergoing Revision Arthroplasty of the Hip or Knee Joint

“…Our results, therefore, suggest that in patients with PJI, all three pathways may be activated. Inhibition of the activation cascade was previously discussed as a therapy option in patients with, for example, spondyloarthropathies [ 19 ]. Whether such approaches might be beneficial in the treatment of PJI can be further investigated.…”